Fusion Antibodies plc (LON:FAB – Get Free Report)’s share price traded up 14.1% during mid-day trading on Tuesday . The company traded as high as GBX 11 and last traded at GBX 10.55. 1,644,497 shares changed hands during mid-day trading, an increase of 288% from the average session volume of 424,310 shares. The stock had previously closed at GBX 9.25.
Fusion Antibodies Stock Performance
The stock has a market cap of £13.20 million, a price-to-earnings ratio of -7.03 and a beta of 1.24. The company has a current ratio of 1.80, a quick ratio of 2.36 and a debt-to-equity ratio of 92.42. The firm has a fifty day simple moving average of GBX 10.84 and a 200-day simple moving average of GBX 12.16.
Fusion Antibodies (LON:FAB – Get Free Report) last released its quarterly earnings data on Monday, September 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative net margin of 91.92% and a negative return on equity of 210.32%. Analysts forecast that Fusion Antibodies plc will post -129.9999875 EPS for the current fiscal year.
About Fusion Antibodies
Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.
Featured Articles
- Five stocks we like better than Fusion Antibodies
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Fusion Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
